746 Results for "

Mutations

" in MedChemExpress (MCE) Product Catalog:
Products (746)

746 Results for "Mutations" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-153321
CAS No.: 2649400-34-8
Purity:  98.67%
Synonyms: NX-5948; BTK-IN-24
Target:  

PROTACs Btk

Research Areas:  

Inflammation/Immunology

Bexobrutideg (NX-5948) is an orally active chimeric targeting molecule (CTM) that induces specific BTK protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. Bexobrutideg mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models that contain either wild-type BTK or BTKi-resistant mutations. Bexobrutideg is efficacious in a mouse collageninduced arthritis (CIA) model. Bexobrutideg can cross the blood brain barrier (BBB). Bexobrutideg is a PROTAC composed of the ligand for target protein, a linker, and a cereblon E3 ligase (CRBN) complex (Red: BTK ligand (HY-170324); Blue: CRBN ligand (HY-171893); Black: linker) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-16743
CAS No.: 1401090-53-6
Synonyms: Venglustat; SAR402671; GZ402671
Research Areas:  

Metabolic Disease

Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-16743A
CAS No.: 1629063-78-0
Synonyms: Venglustat (L-Malic acid); SAR402671 (L-Malic acid); GZ402671 (L-Malic acid)
Research Areas:  

Metabolic Disease

Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-16743B
CAS No.: 1629063-80-4
Synonyms: Venglustat succinate; SAR402671 succinate; GZ402671 succinate
Research Areas:  

Neurological Disease

Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-156633
CAS No.: 2636846-41-6
Purity:  99.78%
Synonyms: PC14586
Target:  

MDM-2/p53

Research Areas:  

Cancer

Rezatapopt (PC14586) is an orally active antineoplastic agent. Rezatapopt binds to a pocket created by the TP53 Y220C mutation. Rezatapopt restores p53 tumor suppressor functions by stabilization of the p53 protein structure. Rezatapopt demonstrates tumor inhibition and regression in mouse models with established human tumor xenografts harboring the TP53 Y220C mutation .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-131003
CAS No.: 1505515-69-4
Purity:  99.78%
Synonyms: DS-6051b; AB-106; IBI-344
Target:  

ROS Kinase

Research Areas:  

Cancer

Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-153342
CAS No.: 2750830-09-0
Purity:  98.99%
Synonyms: ARV-766; JSB462
Research Areas:  

Cancer

Luxdegalutamide (ARV-766) is an orally active protein hydrolysis targeted chimeric (PROTAC) targeting androgen receptor (AR), which can degrade AR resistance related mutants, including T878/H875/L702 mutants. Luxdegalutamide has anti-tumor activity and can be used in the study of castration resistant prostate cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-112299
CAS No.: 1661854-97-2
Purity:  99.81%
Synonyms: TAS6417; CLN-081
Target:  

EGFR Apoptosis

Research Areas:  

Cancer

Zipalertinib (TAS6417; CLN-081) is a highly effective, orally active and pan-mutation-selective EGFR tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC50 values ranging from 1.1-8.0 nM .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-134819A
CAS No.: 2418594-00-8
Purity:  99.79%
Synonyms: (-)-trans-ML-SI3
Target:  

TRP Channel

Research Areas:  

Neurological Disease

(1R,2R)-ML-SI3 is an isomer of ML-SI3 and a potent inhibitor of three isoforms of TRPML. (1R,2R)-ML-SI3 inhibits TRPMLs with IC50s of 1.6 μM (TRPML1), 2.3 μM (TRPML2), and 12.5 μM (TRPML3), respectively .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-139279
CAS No.: 2648641-36-3
Purity:  98.02%
Synonyms: TPX-0131
Research Areas:  

Cancer

Zotizalkib (TPX-0131) is a potent, selective, CNS-penetrant and orally active inhibitor of wild-type ALK (IC50 of 1.4 nM) and ALK-resistant mutation, e.g. G1202R (IC50 of 0.3 nM), L1196M (IC50 of 0.3 nM). Zotizalkib has strong antitumor activities .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-126490
CAS No.: 11006-33-0
Purity:  ≥95.0%
Phleomycin is a copper-dependent DNA damaging agent and antibiotic with antitumor activity. Phleomycin binds to DNA and produces ROS in the presence of reducing agents (such as dithiothreitol and glutathione), inducing single-strand and double-strand breaks in DNA. Phleomycin can induce cell apoptosis or mutation and is widely used in cancer inhibition, microbial genetic transformation (as a screening marker to improve fungal transformation efficiency) and DNA repair mechanism research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-153268
CAS No.: 2607829-38-7
Purity:  99.03%
Synonyms: BDTX-1535; EGFR-IN-76
Target:  

EGFR

Silevertinib (BDTX-1535) is an irreversible, brain-penetrant, selective and orally active EGFR inhibitor with wild-type EGFR-sparing. Silevertinib targets key EGFR resistance mutations, including the kinase domain (C797S, L718Q, G724S, S768I), extracellular domain (EGFRvIII, A289X), and EGFR amplification. Silevertinib exerts anti-tumor activity with well tolerated in vivo. Silevertinib can be used for non-small cell lung cancer (NSCLC) and glioblastoma (GBM) research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-18303
CAS No.: 882663-88-9
Target:  

Src VEGFR p38 MAPK JAK

Research Areas:  

Inflammation/Immunology

AMG-47a is an orally active, ATP-competitive Lck inhibitor (IC50=0.2 nM). AMG-47a inhibits VEGF2, p38α, p38α, Jak3, MLR, and IL-2 with IC50 of 1 nM, 3 nM, 72 nM, 30 nM, and 21 nM, respectively. AMG-47a reduces T cell activation and the production of cytokines such as TGF-β, exerting anti-inflammatory and anti-fibrotic activities. AMG-47a can be used in the research of autoimmune diseases, pulmonary fibrosis, and KRAS mutation-associated cancers[1][2][3].
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15466
CAS No.: 1007207-67-1
Purity:  99.01%
Synonyms: CH5132799
Target:  

PI3K Apoptosis mTOR Akt

Research Areas:  

Cancer

Izorlisib (CH5132799) is an orally active, selective Class I PI3K inhibitor with an IC50 value of 14 nM against PI3Kα. Izorlisib specifically inhibits Class I PI3K (particularly PI3Kα and its mutants) and blocks the PI3K/Akt/mTOR pathway; this leads to cell cycle arrest at the G1 phase and apoptosis without triggering feedback activation of Akt by competitively binding to the ATP-binding site of PI3K. Izorlisib can be used in research on cancers harboring PIK3CA mutations or PTEN loss (such as breast, ovarian, prostate, and endometrial cancers) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N1073
CAS No.: 51225-30-0
Synonyms: 6-Isopentenylgenistein; Erythrinin B
Wighteone (6-Isopentenylgenistein; Erythrinin B) is a prenylated isoflavone that acts as a HSP90/EGFR L858R/T790M inhibitor and antifungal agent. Wighteone reduces the expression level of HSP90, blocks EGF-induced phosphorylation of EGFR, and thereby inhibits the downstream ERK and AKT signaling pathways. Wighteone induces cell cycle redistribution, inhibits proliferation and triggers apoptosis in cancer cells. Wighteone can be isolated from Erythrina suberosa, and can also be induced to synthesize in Lotus japonicus under specific conditions. Wighteone can be used to study HER2-positive breast cancer, leukemia, non-small cell lung cancer with EGFR L858R/T790M mutation, and fungal infections .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-114231B
CAS No.: 2244622-33-9
Purity:  ≥98.0%
Synonyms: ELX-02 disulfate; NB-124 disulfate
Target:  

DNA/RNA Synthesis

Research Areas:  

Inflammation/Immunology

Exaluren (ELX-02; NB-124) disulfate is an synthetic eukaryotic ribosome-selective glycoside that induces read-through of nonsense mutations, resulting in normally localized full-length functional proteins. Exaluren disulfate is used for the research of cystic fibrosis caused by nonsense mutations .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-161111
CAS No.: 3056394-59-0
Target:  

Ser/Thr Kinase

Research Areas:  

Cancer

KVS0001 is a selective SMG1 inhibitor. KVS0001 elevates the expression of transcripts and proteins resulting from truncating mutations. KVS0001 increased the presentation of immune-targetable HLA class I-associated peptides from nonsense-mediated decay (NMD)-downregulated proteins on the surface of cancer cells. KVS0001 exerts anti-tumor properties and can be studied in research for NMD-related diseases, including cancer and inherited diseases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-114231
CAS No.: 1375073-93-0
Synonyms: ELX-02; NB-124
Target:  

Drug Derivative

Research Areas:  

Inflammation/Immunology

Exaluren (ELX-02; NB-124) is an synthetic eukaryotic ribosome-selective glycoside that induces read-through of nonsense mutations, resulting in normally localized full-length functional proteins. Exaluren is used for the research of cystic fibrosis caused by nonsense mutations .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10943
CAS No.: 839706-07-9
Purity:  99.70%
Target:  

Bcr-Abl Ack1

Research Areas:  

Cancer

GNF-7 is a multikinase inhibitor. GNF-7 is a Bcr-Abl inhibitor, with IC50s of 133 nM and 61 nM for Bcr-Abl WT and Bcr-Abl T315I, respectively. GNF-7 also possesses inhibitory activity against both ACK1 (activated CDC42 kinase 1) and GCK (germinal center kinase) with IC50s of 25 nM and 8 nM, respectively. GNF-7 can be used for the research of hematologic malignancies .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-157395
CAS No.: 2361327-06-0
Purity:  98.59%
Target:  

Pyruvate Kinase

Research Areas:  

Cancer

malonyl-NAC increases cellular propylation, resulting in reduced endogenous GAPDH activity. malonyl-NAC increases GAPDH malonylation in cells and inhibits pyruvate kinase activity. In addition, malonyl-NAC limits the metabolism and proliferation of a highly glycolytic kidney cancer cell line harboring a tricarboxylic acid cycle mutation .
loading...
    loading...